INTRODUCTION
The presence of 3,3'-diiodothyronine (3,3'-T2)1 in the thyroid gland and the plasma of the rat was demonstrated originally by Roche et al. (1) . Subsequently, the same group showed that radioiodine-labeled 3,5,3'-triiodothyronine (T3) and 3,3',5'-triiodothyronine (reverse T3[rT3]) were converted to 3,3'-T2 in the rat (2). Flock et al. (3, 4) reported similar findings in the intact dog. Chopra et al. (5) have recently presented evidence in rat liver homogenates that the conversion of rT3 and of T3 to 3,3'-T2 is enzymatic in nature.
Three groups have described radioimmunoassays for 3,3'-T2 in normal human serum, although the reported levels do not agree (6) (7) (8) . No quantitative estimates have been made, however, of the turnover of 3,3'-T2 in humans. In an early study, Stanbury and Morris (9) using 131I-3,3'-D,L-T2 administered to nor- ' Abbreviations used in this paper: ANS, 8-anilino-L-naphaline sulfonic acid; C, control group; CR, clearance rate; CV, coefficient of variance; H, hypothyroid group; PR, production rate; 3,3'-T2, 3,3'-L-diiodothyronine; T3, triiodothyronine; rT3, reverse T3; T4, thyroxine; TBG, thyroxine-binding globulin. mal subjects in a single bolus injection, found extremely rapid disappearance of tracer from plasma and accumulation of radioiodide in the urine, indicating a high rate of deiodination of this compound.
The present study was initiated to assess the absolute production rate of 3,3'-T2 in man, using the technique of constant tracer infusion to estimate plasma clearance and a specific radioimmunoassay to measure plasma concentration of this substance. In addition to studies of subjects with intact thyroid glands, measurements of 3,3'-T2 kinetics were done in athyreotic patients who were maintained eumetabolic on L-thyroxine (T4) to determine the importance of extrathyroidal sources of 3,3'-T2 relative to direct thyroidal secretion. In some of the athyreotic subjects on T4 therapy, turnover studies of T3 and rT3 were performed as well. In three additional cases receiving T3 as maintenance therapy, T3 and 3,3'-T2 kinetics were determined. These studies allowed an assessment of the relative contributions of T3 and of rT3 as immediate precursors of 3,3'-T2 in humans.
METHODS
The subjects participating in this investigation were from the outpatient service of the San Francisco Veterans Administration Hospital. All subjects gave written consent, having been informed of the purpose and nature of the study. Seven male euthyroid control subjects included four normal volunteers and three patients with mild nonthyroidal, nonsystemic illnesses. The eight athyreotic adult males were eumetabolic by clinical and laboratory criteria at the time of study. Five subjects were receiving full replacement doses of L-T4 (Synthroid, Flint Laboratories, Deerfield, Ill.) and three were maintained on L-T3 (Cytomel, Smith Kline & French Laboratories, Philadelphia, Pa.). None of the patients was taking any drug known to interfere with normal thyroid function or to affect the metabolism of thyroid hormones. The mean T4 replacement dose in the athyreotics was 145 ,ug/day. Radioimmunoassay of 3,3'-T2. Unlabeled 3,3'-L-T2 and the various other thyroid hormone analogues and derivatives were obtained through the courtesy of Dr. Eugene Jorgensen, University of California, San Francisco, Calif. The 1251-3,3'-T2 (labeled presumably in the 3-position) was prepared from 3,3'-L-T2 by Abbott Laboratories, North Chicago, Ill. Specific activity ranged from 250 to 350 ,tCi/,ug. At the time of use, each lot of labeled tracer was analyzed for radiochemical purity by Sephadex G-25 column chromatography (by the method described below) and was found to contain <5% of labeled iodide and <1% of labeled rT3. A conjugate of 3,3'-T2 and 3,3'-T2-bovine serum was prepared by the method of Gharib et al. (10) . The carbodiimide (1-cyclohexyl-3-carbodiimide metho-p-toluene-sulfonate) was obtained from Aldrich Chemical Co., Inc., Milwaukee, Wis., and dimethylformamide from Fisher Scientific Co., Pittsburgh, Pa. Antiserum was harvested from rabbits immunized with the 3,3'-T2-bovine serum albumin conjugate emulsified in complete Freund's adjuvant (Miles Laboratories, Inc., Elkhart, Ind.) and pertussis vaccine (Eli Lilly and Company, Indianapolis, Ind.). The antiserum selected for the present study bound 30-35% of tracer amounts of radioactive 3,3'-T2 in a final dilution of 1:10,000. The binding of ligand to serum proteins was inhibited by 8-anilino-L-naphthaline sulfonic acid (ANS), supplied by Eastman Kodak Co., Rochester, N. Y.
To determine the need for ANS in our assay we compared the percent (% B/T) of 1251-3,3'-T2 bound by a fixed concentration of antiserum in barbital buffer (0.07 M barbital, pH 8.6) with that bound in iodothyronine-free serum (11 (14) (15) (16) .
Constant-infusion 3,3'-T2 studies. Subjects were hospitalized on a metabolic ward for the duration of the study. Thyroidal radioiodine uptake was minimized in all euthyroid subjects by giving a saturated solution of potassium iodide orally, 10 In all tracer studies, dose standards were prepared by adding aliquots of tracer doses to undiluted pooled normal serum. These standards were processed in an identical manner to the plasma samples.
Analysis of sera from kinetics studies. Multiple serum samples, collected during the 1251-3,3'-T2 infusion studies, were analyzed by column chromatography employing Sephadex G-25F, by a modification of the method described by Green (17) . A column of Sephadex G-25F, bed volume 2.05 x 25 cm, was equilibrated with 0.5 M NaCl-0.054 N NaOH (pH 11.3). Samples and standards (3 ml) were diluted with an equal volume of diluent (1.0 M NaCl in 0.2 M phosphate buffer, pH 6.5) before application to the column. Iodoprotein, iodide, and 1251-3,3'-T2 were eluted in suiccession by 0.005 M NaCl + 0.1 N NaOH, pH 11.8. 20 mM sodium metabisulfite was added to the equilibrating and eluting solution to minimize deiodination. From 140 to 160 fractions (3 ml each) were collected. Each fraction was counted (10 min) in an automatic well-type gamma counter (mean background = 40 cpm). Those fractions included in the 1251-3,3'-T2 region (fractions 75-120, approximately) were counted again for longer periods, up to 100 min each, to obtain a relative counting error of 3% or less.
An average of 98.2+±4.7% (SD) of the total 125I in samples and standards applied (40 runs) to the column was recovered in the eluate. Of the total 1251 in the standards prepared from the infusate, 86.6+7.5% was eluted as 1251-3,3'-T2. The remainder of the 1251 was in the form of iodide and iodoprotein in approximately equal proportions. The mean 125I-3,3'-T2 concentration in two or more samples taken during the steadystate was used in the determination of the clearance rate (CR).
131I-T3 and 1251-rT3 were separated from other labeled components of serum by means of anion-exchange resin columns (Curtis Nuclear Corp., Los Angeles, Calif.) according to the method described by Nicoloff et al. (18) . The experience of our laboratory with this method of analysis for 131I-T3 and 125I-rT3 has been described (12) . All samples and dose standards from a kinetics study were processed at the same time. For each tracer, the results are expressed as the percent of the injected dose per liter of serum.
Calculations. In the constant infusion 3,3'-T2 study the CR was calculated from the infusion rate divided by the steady-state serum concentration of 1251-3,3'-T2 achieved during the infusion (12) . The production rate (PR) was calculated from CR multiplied by the serum concentration of stable 3,3'-T2 (mean of three to five samples taken during infusion). In each single injection (T3 and rT3) study, the plasma disappearance curve for each tracer was fit to a three-exponential function by the method of least squares. From the Y-intercepts and slopes of the exponential components the CR was computed by the method of Tait (19) . The (20) .
RESULTS

Radioimmunoassay for L-3,3'-T2
Specificity. The reactivities of various compounds relative to 3,3'-T2 were calculated on the basis of the molar amount that caused 50% inhibition ofthe binding of 1251-3,3'-T2 to antibody (Table I ). The monoiodothyronines, 3-T1 and 3'-T1, demonstrated the greatest degree of cross-reactivity. T4 and T3 demonstrated negligible reactivity, whereas rT3 showed a cross-reactivity of 0.6%. The calculated total contribution of T4, T3, and rT3 was <5% of the observed 3,3'-T2 concentration, based on the cross-reactivity values and the known concentrations of these iodothyronines in normal serum.
Analysis of the autoradiographic bands eluted from the thin-layer chromatograph of rat bile demonstrated the presence of two labeled conjugates. The eluted bands containing the conjugates represented 52% of the total biliary counts applied to the chromatograph.
Enzymatic hydrolysis of these bands with ,8-glucuronidase and Mylase-P in separate experiments released 1251-3,3'-T2. Before enzymatic hydrolysis there was no detectable binding by specific 3,3'-T2-binding antibody of the radioactive conjugates of 3,3'-T2. In control experiments it was determined that the enzymes did not affect the antibody binding of tracer.
Standard curve. Fig. 1 demonstrates a typical standard curve of 3,3'-T2 radioimmunoassay. Significant inhibition of the binding of 1251-3,3'-T2 to antiserum was evident with as little as 20 pg of stable 3,3'-T2/ml serum (4 pg/tube). The sensitivity of the assay was determined from t-test analyses of data from multiple standard curves performed in triplicate. The data were expressed as percent bound (mean±+SD) and the first point on each standard curve demonstrating a significant difference (P < 0.05) at >2 SD from the ml) and a hypothyroid serum (3.0 ng/100 ml) sample were enriched with 3.0 ng/100 ml. The percent recoveries were 112 and 100, respectively. A hyperthyroid (10.0 ng/100 ml) and a high TBG serum (5.0 ng/ 100 ml) sample were enriched with 9.0 ngIlO0 ml. The percent recoveries were 107 and 93, respectively. The mean 3,3'-T2 recovery from the series of experiments 0.01 0.1 1 was 103%.
* 2 per assay tube Reproducibility. The intra-and interassay repro-'-T2 radioimmunoassay and ducibility was examined in samples with variable 3,3'-serum from a hyperthyroid T2 concentrations. The intra-assay coefficient of varia--T2 by antibody.
tion (SD/mean x 100) was 6.2%. The mean coefficient of variation of 10 specimens, varying in 3,3'-T2 conassay sensitivity. Fig. 1 centration from 2.0 to 9.0 ng/100 ml and assayed in nding cturve of dilutions duplicate four times in different assays, was 11.6%. m) of serum from a hySerum 3,3'-T2 concentration in health and disease. 1 to the standard curve. 3,3'-Diiodothyronine Production in Man6.0± 1.0 ng/100 ml with a range from 4.5 to 7.8 ng/100 ml. The mean serum 3,3'-T2 concentration in 25 untreated hyperthyroid patients was significantly higher than in normal subjects (P < 0.01) but extended over a wide range from 3.0 to 21.0 ng/100 ml. In the 17 untreated hypothyroid patients the mean serum 3,3'-T2 concentration was significantly lower than in normal subjects (P < 0.001). The mean serum 3,3'-T2 in 11 hypothyroid patients maintained eumetabolic on L-T4 (100-200,g/day) was not significantly different from the normal subjects. In 10 patients suffering from acute nonthyroidal systemic illness with decreased total serum T3 (49±22 ng/100 ml) and elevated rT3 (43+25 ng/100 ml), the mean 3,3'-T2 level was within the normal range. 1251-3,3'-T2 . The elution position of some of these metabolites, 3,3'-T2 conjugates and 3'-T1, was determined in separate column analyses. Fig. 3 also demonstrates that the elution profile of stable 3,3'-T2, added to the 6-h sample before analysis on the Sephadex G-25 column, is superimposable on the 1251-3,3'-T2 peak. This confirms the position of 1251-3,3'-T2 in the eluted fractions from the column. In each subject studied at least two samples collected during the infusion period were analyzed to determine the 1251-3,3'-T2 concentration.
The clearance of 1251-3,3'-T2 was determined by the constant infusion method. In initial studies three separate serum samples collected during the interval from 2 h to the end of the infusion period were analyzed for 125I-3,3'-T2. Fig. 4 shows that the concentration of 1251-3,3'-T2 concentration in the final sample to that in the initial sample averaged 0.95+0.08 in the entire group, again confirming that an isotopic steady state had been reached. In every case calculation of the clearance was based on the average of the 125I-3,3'-T2 concentrations in all serum samples collected beyond the 2-h point of the inftusion.
The plasma concentration of 3,3'-T2 and the kinetic parameters obtained in each of the subjects studied are shown in Table III . The mean total serum 3,3'-T2 concentration in the control (C) group (n = 7) was not significantly different from the T4-treated hypothyroid (H) group (n = 5). The mean total serum T4 concentrations and free T4 indices (normal 0.5-1.5) were almost identical for the two groups, at 7.7±1.0 ,ug/100 ml; 0.9±0.2 in C, and 7.9+1.2 ,ug/100 ml; 0.9+0.3 in H, respectively. The 3,3'-T2 CR averaged 628+218 liters/day in C and 840+377 liters/day in H. 3,3'-T2 PR were not significantly different (39.8±19.8 ,ug/day in C vs. 33.9±+12.5 ,ug/day in H).
To determine the quantitative significance of 3,3'-T2 as a product of the metabolism of T3 and rT3, the absolute turnover rates of T3, rT3, and 3,3'-T2 were determined in three athyreotic subjects on T4 replacement. Table IV gives the kinetics studies results of each of these iodothyronines in the three subjects. The 3,3'-T2 PR in each case was close to the combined PR of T3 and rT3. The average ratio of 3,3'-T2 PR (nanomoles per day) to the combined triiodothyronine PR (nanomoles per day) was 1.08±0.10.
To estimate the magnitude of conversion of T3 to 3,3'-T2, kinetics studies were conducted on three athyreotic subjects receiving L-T3 replacement at three or four hourly intervals. A single pulse injection of 1311_ T3 and a constant 8-h infusion of 1251-3,3'-T2 were given. The PR of each was determined as described above. Table V presents the 3,3'-T2 and T3 kinetics in each subject. The mean total serum 3,3'-T2 concentration (3.4 + 1.2 ng100 ml) was significantly lower than in the C group (6.0±+1.0 ng/100 ml) (P < 0.001). The 3,3'-T2 CR averaged 653±144 liters/day and the 3,3'-T2 PR, 22 .6+10.7 ,ug/day. Although the latter value was not significantly less than the C group (39.8±19.8 ,ug/ day), a study of a large number of T3-treated hypothyroid subjects could very well reveal a difference in 3,3'-T2 PR compared to controls. The mean total serum T3 concentration was high (1.53+0.28 ng/100 ml) in Significantly different from the control mean: 1 1 (P < 0.01), ¶ (P < 0.02), **(P < 0.02).
comparison to the control subjects (1.03±0.15 ng/100 ml) (P < 0.001). Wu et al. (6) , who employed ethanol extraction of serum and the recently reported value, 4.3+±2.0 ng/100 ml, from Burger and Sakoloff (8) , who analyzed unextracted serum. The presence of 3,3'-T2 in normal whole serum at a slightly higher concentration (17.0±+1.0 ng/100 ml) measured by radioimmunoassay has also been reported by Burman et al. (7) .
In hyperthyroidism, serum 3,3'-T2, like T4, T3, and rT3, was elevated on the average. There was, however, a wide range of values from moderate elevation to markedly high serum 3,3'-T2 levels. The absence of a positive correlation between the serum total T4 and the 3,3'-T2 levels has been noted previously (22) . It may be due to an increased 3,3'-T2 CR, as preliminary studies in our laboratory demonstrate increased 3,3'-T2 CR in hyperthyroidism (23) . The normal serum 3,3'-T2 levels in patients with elevated TBG concentration is consistent with the reported low binding affinity of 3,3'-T2 for TBG, compared with T4 (24) , and normal levels in pregnancy (6) .
The finding of normal serum 3,3'-T2 levels in athyreotic subjects maintained eumetabolic on T4 replacement confirms a previous report (22) and suggests that the major source of circulating 3,3'-T2 is extrathyroidal production.
The original analysis of rat thyroglobulin by Roche et al. (1) suggested that 3,3'-T2 was a major component of the iodothyronines present. This finding in the rat was not confirmed by the recent studies of Taurog et al. (25) , who demonstrated that 3,3'-T2 comprised <2% of the total 13'I in the thyroids of severely iodinedeficient rats and even less in the iodine-replete animal. In a recent report Burman et al. (7) found a 3,3'-T2 concentration of 0.4+0.03 ,ug/g in normal thyroid tissue and a lack of a serum 3,3'-T2 response secondary to thyrotropin-releasing hormone stimulation, findings indicative of a minimal rate of thyroidal secretion. That the thyroid gland is not a major source of circulating 3,3'-T2 is confirmed by the similar 3,3'-T2 PR in the euthyroid control group and in the athyreotic subjects in whom the only source of 3,3'-T2 was exogenous T4.
There are no other data available at present to compare with the PR of 3,3'-T2 obtained in this study.
The rate of disappearance from the blood of tracer 3,3'-T2 (as the racemic mixture) in man has been examined in a previous study and found to be extremely rapid (9) . The achievement of a constant plasma level of 125I-3,3'-T2 during the first few hours of a constant infusion is consistent with this finding. However, quantitative estimates of 3,3'-T2 CR have not been reported previously.
The metabolism of 3,3'-T2 would be expected to yield monoiodothyronines, thyronine itself, deaminated derivatives, and conjugated forms. The glucuronic acid conjugate of 3,3'-T2 has been identified in the bile ofthe rat after the injection of labeled 3,3'-T2 (26) and the sulfate conjugate of 3,3'-T2 in the bile and urine of the dog after the administration of labeled T3 (16 5 Uncorrected for body wt. I I Nanomolar ratio of PR.
3,3'-Diiodothyronine Production in Manthe presence of two unidentified compounds in some serum samples chromatographed after the administration of 1311-3,3'-T2. The Sephadex column employed in the present study separates 3,3'-T2 conjugates and 3'-T, from 3,3'-T2. Even if the 3,3'-T2-containing fractions from our columns did include labeled metabolites, however, the calculated CR would have underestimated the true CR in our subjects. The magnitude of 3,3'-T2 PR suggests that it is a major metabolite of the deiodination pathways. Tracer studies in both the rat (2, 27, 28) and the dog (4, 16) demonstrated that both T3 and rT3 are precursors of 3,3'-T2 T Recent in vitro studies by Chopra et al. (5) in rat liver homogenates have demonstrated that both T3 and rT3 are converted to 3,3'-T2. The finding of 5'-deiodination (phenolic ring) of' rT3 to 3,3'-T2 by liver homogenates confirms the previous reports by Flock and Owen (29) who employed perfused rat liver and a recent study of the metabolism of thyroid hormones by cultured monkey hepatocareinoma cells (30) .
There has been no information, however, on the quantitative significance of 3,3'-T2 as a metabolite of T3 or rT3 until the present study in humans. The magnitude of3,3'-T2 PR indicates that it is a major metabolite of both triiodothyronines. In all cases studied, the 3,3'-T2 PR was close to the combined (T3 + RT3) PR, accounting for 90-110% of' total turnover. This finding is supported by the demonstration that the conversion of T3 to 3,3'-T2 (in T3-replaced subjects) was a major pathway of T3 metabolism.
The finding that both T3 and rT3 are major precursors of 3,3'-T2 and that the magnitude of their contribution may be variable could explain the observation of a normal serum 3,3'-T2 concentration in acute nonthyroidal systemic illness with low serum T3 but high serum rT3.
Previous studies in normal humans have demonstrated that 5-deiodination of T4 to rT3 is at least as active as 5'-deiodination to T3, the total activity of both pathways accounting for most of the T4 metabolized (12, 31) . The present finding that 3,3'-T2 is the principal product of the metabolism of both rT3 and T3 indicates the importance of 3,3'-T2 as an intermediate in T4 metabolism. Furthermore, the finding implies that the other diiodothyronines, 3,5-T2 and 3',5'-T2, are of only minor quantitative significance.
Early studies by Roche et al. (1) demonstrated that 3,3'-T2 was calorigenically active but this has not been confirmed by subsequent in vivo studies (25, (32) (33) (34) . Recent studies have shown the ability of 3,3'-T2 to enhence the uptake of radioleucine by thymocytes in culture, but the effect was seen only at high concentrations and so its biological significance is not clear (35) . Even if it is not biologically active, 3,3'-T2 must be regarded as a major intermediate in the deiodination of iodothyronines. A recent report by Chopra (36) shows that 3,3'-T2 is a weak inhibitor of the conversion of T4 to T3 in rat liver homogenates. This raises the possibility that 3,3'-T2 may regulate the monodeiodination of T4. Studies are presently in progress in our laboratory to elucidate further the significance of this intermediate in the peripheral metabolism of iodothyronines.
